Business
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a
About this update from Zymeworks Inc.
[{"type":"text","content":"New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting antibody-drug conjugate (ADC)New ADC candidates, including ZW437 and ZW418, demonstrate strong activity across RAS-mutated cancers based on a novel pan-RAS inhibitor ADC platform VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 17-22, 2026 in San Diego, CA. “We are excited to share new clinical and preclinical updates at AACR that highlight the breadth of our ADC portfolio and the continued evolution of our platform technologies,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “In addition to new preclinical combination insights from our ADC candidate ZW191, we will present data from our emerging RAS inhibitor ADC platform and several novel candidates designed to target treatment of RAS mutated cancers, some of the most prevalent oncogenic-driven human cancer types. Together, these findings demonstrate our differentiated approach to ADC design and our commitment to developing innovative therapies for patients with difficult-to-treat cancers.” Oral Presentation Details Title: Results from Part 1 dose escalation of ZWI-ZW191-101 study: Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)–targeting antibody-drug conjugate (ADC), in participants with advanced solid tumorsAbstract: CT306Session: Advances in Precision OncologyDate/Time: Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST) “We look forward to presenting additional clinical data from Part 1 of our Phase 1 trial of ZW191, our FR alpha targeting ADC with our proprietary topoisomerase 1 inhibitor payload, in patients with advanced solid tumors,” said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer of Zymeworks. “The more mature results build on the initial data we presented at...